/PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the.
BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights
Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 – – Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022 – BELLUS Health Inc. a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic … – Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 – – Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022 –
0.10%
At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; (ii) the Company s omnibus incentive plan; (iii) an amendment to the Company s existing stock option plan (the
Amended Option Plan ) and the previous grant of stock options exercisable thereunder; and (iv) an amendment to the Company s articles.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
About Prostate Cancer